This research line includes a multidisciplinary team composed of biologists, medical oncologists and pathologists with the common objective of understanding the molecular alterations involved in cancer to help both in patients´ diagnosis and prognosis. Our main aim is to find new biomarkers and molecular targets that can be used towards a precision medicine, opening new avenues in the therapeutic options, using tissue and liquid biopsies.
Currently, we have a project focused in the possible role as oncogenes of a subset of active L1 retrotransposon elements in lung, colorectal, and head and neck tumours. We have developed a novel targeted sequencing-based method for the detection of high-activity rates of individual L1 elements in cancer samples. This promising tool allows studying the molecular consequences of L1 activation in tumor initiation, progression and treatment response. We believe that its clinical application could change cancer diagnosis and would help oncologists for personalized treatments.
Dra Mónica Martínez-Fernández
Dr Martín Lázaro (Medical Oncology, CHUVI)
Dra Noemi de Dios (Medical Oncology, CHUVI)
Dra Laura Juaneda (Anatomical Pathology, CHUVI)
Dr Máximo Fraga (Anatomical Pathology, CHUS)
Jenifer Brea (Genomes and Disease lab, CIMUS)
Martínez-Fernández M. 2018 “Detecting hot-activity of retrotransposons in human tumours using a novel targeted sequencing-based method. 16th ASEICA INTERNATIONAL CONGRESS. Selected oral communication.
Martínez-Fernández M. 2018. “Detection of High Rates of Somatic Retrotransposition by Agilent SureSelect System in Lung Cancer”. V Edition Biomedical Cancer Research Conference IBCG. Selected oral communication.
Pequeño A, Tubio J, Martínez-Fernández M. 2018. Towards the Identification of Tumor Samples with High Rates of Somatic Retrotransposition by Agilent SureSelect System. II Anual Meeting Cinbio.